UNSPSC 51162702: Ambroxol

This classification denotes a mucolytic agent and expectorant with the molecular formula C13H18Br2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 200168S0CL, chemically known as trans-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol but more generally known as ambroxol, which bears US NIH Compound Identifier 2132. Ambroxol most often comes in base and hydrochloride forms. European Medicines Agency schedules Ambroxol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05397MIG.

UNSPSC 51162702 Ambroxol, a Commodity code, encompasses pharmaceutical products and related services that state and local governments procure for healthcare delivery to incarcerated populations, patients in correctional facilities, and community health programs. Recent solicitations reveal state and local agencies buying parenteral nutrition solutions, intravenous products, naloxone, and drug deactivation systems. The issuing bodies are primarily state departments of corrections and county health authorities. The Washington State Department of Corrections and Seminole County, Florida are active buyers under this code, seeking suppliers capable of managing clinical workflows, maintaining rapid delivery schedules, and meeting strict insurance and compliance standards. Contractors must hold appropriate state business licensure, pass criminal background clearances, and demonstrate documented experience in preparing and monitoring pharmaceutical products, particularly for parenteral nutrition formulations.

Activity concentrates in Washington and Florida based on recent solicitations. The Washington State Department of Corrections posted RFQQK13020 on September 8, 2026, requesting parenteral products, services, and equipment for eight correctional facilities across three regions, with quotes due October 7, 2026; DOC anticipates selecting up to three bidders per region and requires parenteral nutrition bags within 24 hours of order and other parenteral products within 8 hours. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, soliciting 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the county community health building. Both opportunities emphasize fixed pricing, multi-year initial terms, and comprehensive insurance requirements including commercial general liability, professional liability, and cyber liability coverage.